Search research articles
Contact Us
Filters
Showing results (391-400 of 416) with videos related to
Page
of 42
Sort By:
Investigational New Drugs
|
October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
William R Schelman, Anne M Traynor, Kyle D Holen, et al.
Breast Cancer Research and Treatment
|
February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen
Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
International Journal of Epidemiology
|
January 12, 2017
Gene-obesogenic environment interactions in the UK Biobank study
Jessica Tyrrell, Andrew R Wood, Ryan M Ames, et al.
Plos Genetics
|
September 27, 2021
A biallelic SNIP1 Amish founder variant causes a recognizable neurodevelopmental disorder
Zineb Ammous, Lettie E Rawlins, Hannah Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
Evanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group
Judith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Cancer Discovery
|
June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention
James N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Journal of Neuro-Oncology
|
January 12, 2010
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
Kurt A Jaeckle, Karla V Ballman, Caterina Giannini, et al.
Aging
|
April 19, 2019
The acute transcriptional response to resistance exercise: impact of age and contraction mode
Colleen S Deane, Ryan M Ames, Bethan E Phillips, et al.
The Journal of Clinical Investigation
|
May 17, 2013
The genomic landscape of small intestine neuroendocrine tumors
Michaela S Banck, Rahul Kanwar, Amit A Kulkarni, et al.
Page
of 42
Search research articles
Search
Showing results (391-400 of 416) with videos related to
Sort By:
Page
of 42
Investigational New Drugs
|
October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
William R Schelman, Anne M Traynor, Kyle D Holen, et al.
Breast Cancer Research and Treatment
|
February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen
Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
International Journal of Epidemiology
|
January 12, 2017
Gene-obesogenic environment interactions in the UK Biobank study
Jessica Tyrrell, Andrew R Wood, Ryan M Ames, et al.
Plos Genetics
|
September 27, 2021
A biallelic SNIP1 Amish founder variant causes a recognizable neurodevelopmental disorder
Zineb Ammous, Lettie E Rawlins, Hannah Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
Evanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2011
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group
Judith G Villablanca, Wendy B London, Arlene Naranjo, et al.
Cancer Discovery
|
June 15, 2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention
James N Ingle, Mohan Liu, D Lawrence Wickerham, et al.
Journal of Neuro-Oncology
|
January 12, 2010
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
Kurt A Jaeckle, Karla V Ballman, Caterina Giannini, et al.
Aging
|
April 19, 2019
The acute transcriptional response to resistance exercise: impact of age and contraction mode
Colleen S Deane, Ryan M Ames, Bethan E Phillips, et al.
The Journal of Clinical Investigation
|
May 17, 2013
The genomic landscape of small intestine neuroendocrine tumors
Michaela S Banck, Rahul Kanwar, Amit A Kulkarni, et al.
Page
of 42